Arvinas Past Earnings Performance
Past criteria checks 0/6
Arvinashan disminuido a un ritmo medio anual de -16.5%, mientras que en la industria Pharmaceuticals los ingresos han sido de growing a 8.5% anuales. Los ingresos han sido growing a una tasa media anual de 46.4%.
Key information
-22.3%
Earnings growth rate
16.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 41.3% |
| Return on equity | -55.7% |
| Net Margin | -467.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Arvinas: Behind The Huge Rally
Mar 03What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You
Feb 25
News Flash: Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts
Aug 13There's Reason For Concern Over Arvinas, Inc.'s (NASDAQ:ARVN) Price
May 05Calculating The Fair Value Of Arvinas, Inc. (NASDAQ:ARVN)
Feb 24Arvinas initiated Overweight at Barclays on attractive therapeutic platform
Sep 09Arvinas a buy at Piper Sandler following failure of Sanofi breast cancer treatment
Aug 19Arvinas: Still Holding, Just Not Buying More
May 23Arvinas: One Of The Most Interesting Science-Heavy Emerging Biopharma
Feb 07Arvinas: 2022 Is Full Of Catalysts For This Protein Degrader Pioneer
Nov 19Revenue & Expenses BreakdownBeta
How Arvinas makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 79 | -367 | 100 | 380 |
| 30 Sep 23 | 159 | -295 | 88 | 383 |
| 30 Jun 23 | 158 | -298 | 86 | 374 |
| 31 Mar 23 | 137 | -301 | 84 | 346 |
| 31 Dec 22 | 131 | -282 | 80 | 315 |
| 30 Sep 22 | 127 | -253 | 83 | 279 |
| 30 Jun 22 | 103 | -233 | 79 | 242 |
| 31 Mar 22 | 75 | -213 | 70 | 210 |
| 31 Dec 21 | 54 | -191 | 62 | 180 |
| 30 Sep 21 | 23 | -180 | 55 | 152 |
| 30 Jun 21 | 21 | -164 | 48 | 141 |
| 31 Mar 21 | 21 | -139 | 43 | 122 |
| 31 Dec 20 | 26 | -119 | 38 | 108 |
| 30 Sep 20 | 24 | -99 | 33 | 96 |
| 30 Jun 20 | 47 | -86 | 32 | 82 |
| 31 Mar 20 | 45 | -78 | 30 | 75 |
| 31 Dec 19 | 43 | -70 | 27 | 67 |
| 30 Sep 19 | 42 | -65 | 26 | 61 |
| 30 Jun 19 | 15 | -173 | 22 | 58 |
| 31 Mar 19 | 14 | -179 | 17 | 52 |
| 31 Dec 18 | 14 | -240 | 13 | 45 |
| 30 Sep 18 | 13 | -233 | 8 | 37 |
| 30 Jun 18 | 12 | -114 | 5 | 31 |
| 31 Mar 18 | 10 | -98 | 4 | 29 |
| 31 Dec 17 | 8 | -29 | 4 | 29 |
| 31 Dec 16 | 7 | -12 | 3 | 20 |
Beneficios de calidad: ARVN actualmente no es rentable.
Creciente margen de beneficios: ARVN actualmente no es rentable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Tendencia de beneficios: ARVN no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 16.5% al año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de ARVN en el último año con su media de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: ARVN no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el del sector Pharmaceuticals (-17.3%).
Return on Equity
Alto ROE: ARVN tiene un Rendimiento de los fondos propios negativo (-64.61%), ya que actualmente no es rentable.